An introductory review of post-resection chemotherapeutics for primary brain tumors.

Meaghan McGovern, Michaela Scanlon, Amanda Stanton, Brandon Lucke-Wold

Open access · diamondAbstract readReview

In one paragraph

Review in Exploration of targeted anti-tumor therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.3field-weighted citation impact, top 35% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Meaghan McGovernSchool of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID https://orcid.org/0000-0002-6355-5500

Michaela ScanlonSchool of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.ORCID https://orcid.org/0009-0001-7841-7063

Amanda StantonDepartment of Neurosurgery, University of Florida, Gainesville, FL 32608, USA.ORCID https://orcid.org/0000-0003-2985-7799

Brandon Lucke-WoldDepartment of Neurosurgery, University of Florida, Gainesville, FL 32608, USA.ORCID https://orcid.org/0000-0001-6577-4080

Uniformed Services University of the Health Sciences · USUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of central nervous system (CNS) tumors is complicated by high rates of recurrence and treatment resistance that contribute to high morbidity and mortality (Nat Rev Neurol. 2022;18:221-36. doi: 10.1038/s41582-022-00621-0). One of the challenges of treating these tumors is the limited permeability of the blood brain barrier (BBB). Early pharmacologic treatments worked to overcome the BBB by targeting vulnerabilities in the tumor cell replication process directly through alkylating agents like temozolomide. However, as advancements have been made options have expanded to include immunologic targets through the use of monoclonal antibodies. In the future, treatment will likely continue to focus on the use of immunotherapies, as well as emerging technology like the use of low-intensity focused ultrasound (LIFU). Ultimately, this paper serves as an introductory overview of current therapeutic options for post-resection primary brain tumors, as well as a look towards future work and emerging treatment options.

Indexed as

blood brain barrierChemotherapeuticsprimary central nervous system tumor

Identifiers

PMID37455829

DOI10.37349/etat.2023.00150

PMCPMC10344890

OpenAlexW4382651667

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.